Cochlear reaffirms $330–350M profit guidance
Hearing implant maker Cochlear (ASX:COH) reaffirmed its FY27 underlying net profit forecast of $330–$350 million.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Hearing implant maker Cochlear (ASX:COH) reaffirmed its FY27 underlying net profit forecast of $330–$350 million.
Imricor Medical Systems (ASX:IMR) recorded a 437% revenue increase to US$188,000 for Q3 2026 as US sales began.
Clarity Pharmaceuticals (ASX:CU6) received a US Food and Drug Administration breakthrough therapy designation for 64Cu-SAR-bisPSMA.
BlinkLab (ASX:BB1) reported that its smartphone-based diagnostic tool showed a 54 percentage point performance gap between participants with genetic autism and control groups.
Anagenics (ASX:AN1) entered into a binding agreement to acquire Australian natural skin-health brand Bio-First for $50,000.
Anteris Technologies (ASX:AVR) reported third-quarter operational progress for the period ended Sept. 30, driven by global heart-valve trial activity.
Syntara (ASX:SNT) has halted enrolment in its Phase 1b clinical study evaluating topical pan-lysyl oxidase inhibitor SNT-9465 for hypertrophic scars.
Immutep (ASX:IMM) reported positive trial data showing that its experimental drug IMP761 safely suppressed immune reactions across seven dose levels ranging from 0.03 mg/kg to 14 mg/kg.
Memphasys (ASX:MEM) secured a two-year public healthcare agreement in New Zealand covering a minimum of 1,200 Felix cartridges.
LTR Pharma (ASX:LTP) secured Indian Patent No. 605429 for its intranasal formulation technology covering erectile dysfunction treatments through May 2041.
Entropy Neurodynamics (ASX:ENP) secured a South African patent for its psilocin crystalline formulations running through September 2043.
BTC Health (ASX:BTC) signed a new exclusive distribution agreement with Exstent to sell its ExoVasc PEARS cardiac device in both Australia and India.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade